Are Analysts Bullish Ligand Pharmaceuticals Inc. (NASDAQ:LGND) After Last Week?

November 7, 2017 - By Nellie Frank

 Are Analysts Bullish Ligand Pharmaceuticals Inc. (NASDAQ:LGND) After Last Week?
Investors sentiment increased to 1.24 in Q2 2017. Its up 0.06, from 1.18 in 2017Q1. It increased, as 22 investors sold Ligand Pharmaceuticals Inc. shares while 79 reduced holdings. 36 funds opened positions while 89 raised stakes. 22.57 million shares or 0.91% more from 22.37 million shares in 2017Q1 were reported.
Ls Investment Advsr Ltd Com holds 0.01% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 1,197 shares. Morgan Stanley invested in 30,049 shares. Geode Cap Management Ltd Limited Liability Company, a Massachusetts-based fund reported 178,258 shares. Prelude Management Ltd holds 1,973 shares or 0.02% of its portfolio. Pub Sector Pension Investment Board reported 9,847 shares. Riverhead Capital Ltd Liability Com holds 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) or 1,798 shares. Cortina Asset Management Limited Com holds 0.34% or 67,026 shares in its portfolio. Granite Investment Prns Limited Liability has 0.91% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 111,426 shares. Parkside Comml Bank Tru accumulated 13 shares. Ontario – Canada-based Royal Commercial Bank Of Canada has invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Nationwide Fund holds 0.01% or 21,553 shares in its portfolio. Ser Automobile Association has invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Pathstone Family Office Ltd Liability Co reported 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Tower Cap Ltd Llc (Trc) has invested 0% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Pinebridge Investments Limited Partnership stated it has 2,508 shares or 0.01% of all its holdings.

Since May 11, 2017, it had 0 insider purchases, and 2 insider sales for $2.01 million activity. Aryeh Jason sold 37,247 shares worth $4.13 million. HIGGINS JOHN L also sold $1.38 million worth of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Friday, June 9.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Ratings Coverage

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ligand Pharmaceuticals had 19 analyst reports since September 3, 2015 according to SRatingsIntel. Roth Capital maintained the stock with “Buy” rating in Thursday, September 3 report. H.C. Wainwright maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Thursday, October 5 with “Buy” rating. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) earned “Overweight” rating by Stephens on Wednesday, April 13. Roth Capital maintained the stock with “Buy” rating in Friday, December 18 report. Roth Capital maintained it with “Buy” rating and $140 target in Wednesday, September 30 report. H.C. Wainwright maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rating on Wednesday, October 5. H.C. Wainwright has “Buy” rating and $160 target. H.C. Wainwright reinitiated the shares of LGND in report on Tuesday, September 5 with “Buy” rating. The rating was maintained by H.C. Wainwright on Wednesday, October 18 with “Buy”. The rating was maintained by TH Capital on Friday, December 18 with “Buy”. TH Capital maintained it with “Buy” rating and $144 target in Thursday, November 19 report. Below is a list of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) latest ratings and price target changes.

18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $157.0 Maintain
11/10/2017 Broker: Roth Capital Rating: Buy New Target: $158.0 Maintain
05/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $157.0 Maintain
05/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $150 Reinitiate
08/08/2017 Broker: Roth Capital Rating: Buy New Target: $135.0000
08/08/2017 Broker: Deutsche Bank Rating: Hold Old Target: $103 New Target: $104 Maintain
17/07/2017 Broker: Deutsche Bank Rating: Hold Old Target: $100 New Target: $103 Maintain

About 44,353 shares traded. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 2.87% since November 7, 2016 and is downtrending. It has underperformed by 19.57% the S&P500.

Ligand Pharmaceuticals Incorporated is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has market cap of $2.88 billion. The Firm is involved in the development and licensing of biopharmaceutical assets. It has a 387.57 P/E ratio. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

More news for Ligand Pharmaceuticals Inc. (NASDAQ:LGND) were recently published by: Nasdaq.com, which released: “What’s in Store for Ligand (LGND) This Earnings Season?” on November 06, 2017. Seekingalpha.com‘s article titled: “Ligand Pharmaceuticals: A Good Long-Term Investment” and published on August 04, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: